AU2010205645B2 - A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted - Google Patents

A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted Download PDF

Info

Publication number
AU2010205645B2
AU2010205645B2 AU2010205645A AU2010205645A AU2010205645B2 AU 2010205645 B2 AU2010205645 B2 AU 2010205645B2 AU 2010205645 A AU2010205645 A AU 2010205645A AU 2010205645 A AU2010205645 A AU 2010205645A AU 2010205645 B2 AU2010205645 B2 AU 2010205645B2
Authority
AU
Australia
Prior art keywords
amino acid
protein
alpha
acid position
icha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010205645A
Other languages
English (en)
Other versions
AU2010205645A1 (en
Inventor
Alfred Collard
Patrice Filee
Moreno Galleni
Alain Jacquet
Olivier Jolois
Noureddine Rhazi
Bernard Taminiau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Liege
Universite Libre de Bruxelles ULB
Centre d'Economie Rurale
Original Assignee
Centre Deconomie Rurale
Universite de Liege
Universite Libre de Bruxelles ULB
Centre d'Economie Rurale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Deconomie Rurale, Universite de Liege, Universite Libre de Bruxelles ULB, Centre d'Economie Rurale filed Critical Centre Deconomie Rurale
Publication of AU2010205645A1 publication Critical patent/AU2010205645A1/en
Application granted granted Critical
Publication of AU2010205645B2 publication Critical patent/AU2010205645B2/en
Assigned to UNIVERSITE LIBRE DE BRUXELLES, CENTRE D'ECONOMIE RURALE, UNIVERSITE DE LIEGE reassignment UNIVERSITE LIBRE DE BRUXELLES Amend patent request/document other than specification (104) Assignors: CENTRE D'ECONOMIE RURALE, UNIVERSITE DE LIEGE, UNIVERSITE LIBRE DE BRUXELLES
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2010205645A 2009-01-19 2010-01-15 A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted Ceased AU2010205645B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09150888A EP2208787A1 (en) 2009-01-19 2009-01-19 A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
EP09150888.7 2009-01-19
PCT/EP2010/050453 WO2010081875A1 (en) 2009-01-19 2010-01-15 A recombinant alpha-hemolysin polypeptide of staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted

Publications (2)

Publication Number Publication Date
AU2010205645A1 AU2010205645A1 (en) 2011-07-14
AU2010205645B2 true AU2010205645B2 (en) 2014-09-04

Family

ID=40811673

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010205645A Ceased AU2010205645B2 (en) 2009-01-19 2010-01-15 A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted

Country Status (7)

Country Link
US (1) US8545853B2 (https=)
EP (2) EP2208787A1 (https=)
JP (1) JP5781941B2 (https=)
AU (1) AU2010205645B2 (https=)
CA (1) CA2749862C (https=)
ES (1) ES2483720T3 (https=)
WO (1) WO2010081875A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
AU2012214677B2 (en) 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
CN103648489A (zh) 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
WO2012178093A1 (en) 2011-06-24 2012-12-27 Electronic Biosciences Inc. High contrast signal to noise ratio device components
CN102977214B (zh) * 2012-09-29 2014-03-12 重庆原伦生物科技有限公司 用于耐甲氧西林金黄色葡萄球菌（mrsa）疫苗的重组蛋白hf2及制备方法和应用
US10047129B2 (en) 2012-12-20 2018-08-14 Electronic Biosciences, Inc. Modified alpha hemolysin polypeptides and methods of use
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CN106103469B (zh) * 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
BR112017006536A2 (pt) * 2014-09-29 2017-12-19 Fujifilm Corp polipeptídeo de ligação ao anticorpo, polipeptídeo de fusão de ligação ao anticorpo, e material de adsorção
CN105641689B (zh) * 2016-01-21 2024-09-10 浙江海隆生物科技股份有限公司 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用
EP3487872A1 (en) 2016-07-22 2019-05-29 Evaxion Biotech ApS Chimeric proteins for inducing immunity towards infection with s. aureus
AU2018243910B2 (en) 2017-03-28 2025-04-10 The Children's Medical Center Corporation A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
JP7525471B2 (ja) 2018-07-24 2024-07-30 メディミューン，エルエルシー Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体
SG11202101973YA (en) 2018-09-12 2021-03-30 Childrens Medical Ct Corp Pneumococcal fusion protein vaccines
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.
WO2024168197A2 (en) * 2023-02-08 2024-08-15 The Regents Of The University Of California Membrane translocation compositions and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005167A1 (en) * 1997-07-25 1999-02-04 University Of Massachusetts Designed protein pores as components for biosensors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
CA2422867A1 (en) * 2000-09-15 2002-04-25 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20060057160A1 (en) * 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
US20080131457A1 (en) 2006-06-12 2008-06-05 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005167A1 (en) * 1997-07-25 1999-02-04 University Of Massachusetts Designed protein pores as components for biosensors

Also Published As

Publication number Publication date
JP5781941B2 (ja) 2015-09-24
EP2382316A1 (en) 2011-11-02
EP2208787A1 (en) 2010-07-21
CA2749862A1 (en) 2010-07-22
CA2749862C (en) 2015-02-24
US20120014983A1 (en) 2012-01-19
AU2010205645A1 (en) 2011-07-14
WO2010081875A1 (en) 2010-07-22
EP2382316B1 (en) 2014-04-23
ES2483720T3 (es) 2014-08-07
JP2013504301A (ja) 2013-02-07
US8545853B2 (en) 2013-10-01

Similar Documents

Publication Publication Date Title
AU2010205645B2 (en) A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
Fattahian et al. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap)
CA2655133C (en) Use of alpha-toxin for treating and preventing staphylococcus infections
US9481723B2 (en) Methods of treating and preventing Staphylococcus aureus infections and associated conditions
KR20070058631A (ko) 면역원성 조성물
US20160244511A1 (en) Cross-reactive staphylococcus aureus antibody sequences
US20180179267A1 (en) Anti-staphylococcus aureus antibody combination preparation
US20160108106A1 (en) Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
AU2006257774B2 (en) Use of Panton-Valentine Leukocidin for treating and preventing Staphylococcus infections
Haghighat et al. Recombinant PBP2a as a vaccine candidate against methicillin-resistant Staphylococcus aureus: immunogenicity and protectivity
US20100015170A1 (en) Flagellin mutant vaccine
US20150165015A1 (en) Use of alpha-toxin for treating and preventing staphylococcus infections
Lun et al. Identification of a conserved cryptic epitope with cross-immunoreactivity in outer membrane protein K (OmpK) from Vibrio species
Faezi et al. Construction, expression, purification and characterization of secretin domain of PilQ and triple PilA-related disulfide loop peptides fusion protein from Pseudomonas aeruginosa
CN116270998A (zh) 基于双受体结合区rbd组装的多价生物毒素抗原疫苗及其制备方法与应用
WO2013034687A1 (en) Avibacterium paragallinarum rtx toxin
WO2008127102A1 (en) S. pnuemoniae transcytosis protein
US20190352377A1 (en) Chimeric antibodies comprising binding domains of phage lysins, bacterial autolysins, bacteriocins, and phage tail or tail fibers
HK1243089A1 (en) Immunogenic pcpa polypeptides and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired